PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

Dec 15, 2022

PETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX₁₀₀ will be highlighted in a podium presentation at the first triennial International Orthopaedic Trauma Association meeting being held on December 14-16, 2022, at the RAI Amsterdam Exhibition and Conference Center in Amsterdam, The Netherlands.

First Triennial Meeting of the International Orthopaedic Trauma Association:

Presentation Title:	Surgical wound infection reduction with locally administered product releasing doxycycline - Implications for orthopaedic trauma injuries
Presenter:	Noam Emanuel, PhD., Chief Scientific Officer, PolyPid Ltd.
Date/Time:	Thursday, December 15, 2022, Infection, wound treatment Session, 8:00 a.m. – 9:00 a.m., room E-108

Event Calendar